Supernus Pharmaceuticals

SUPN

Capitalización de mercado USD 2441 M

ROCKVILLE, Md., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Supernus, Inc. (Nasdaq: SUPN)1 today announced the successful completion of the merger between Supernus Pharmaceuticals, Inc. and Indivior Pharmaceuticals, Inc. (Indivior). The combination officially launches Supernus, Inc., a leading diversified biopharmaceutical company dedicated to treating those living with central nervous system (CNS) diseases.

Supernus Pharmaceuticals, Inc. (SUPN) Q3 2026 Earnings Call Transcript

Supernus Pharmaceuticals (SUPN) came out with quarterly earnings of $0.93 per share, beating the Zacks Consensus Estimate of $0.49 per share. This compares to earnings of $1.01 per share a year ago.

Supernus Pharmaceuticals NASDAQ: SUPN reported record third-quarter revenue and higher sales across its growth portfolio, while management said its planned merger with Indivior Pharmaceuticals is expected to close Nov. 2 following shareholder approvals.

Supernus Pharmaceuticals (NASDAQ:SUPN) reported third-quarter financial results on Thursday. The transcript from the company's third-quarter earnings call has been provided below.

ROCKVILLE, Md., Oct. 29, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced financial results for the third quarter 2026 and associated Company developments.

Supernus (SUPN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Orphan-drug exclusivity provides seven years of market exclusivity for ONAPGO Additionally, the Company submitted an sNDA to the FDA for a second supplier for ONAPGO, with potential approval by mid-year 2027 ROCKVILLE, Md., Oct. 21, 2026 (GLOBE NEWSWIRE) -- Supernus, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, announced today that the U.S. Food and Drug Administration (FDA) has recognized seven years of orphan-drug exclusive approval for ONAPGO (apomorphine HCl) for the treatment of motor fluctuations in adults with advanced Parkinson's disease.

ROCKVILLE, Md., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (Nasdaq: SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that it will report third quarter 2026 financial and business results after the market closes on Thursday, October 29, 2026.

Supernus Pharmaceuticals merges with Indivior, gaining operational control and exposure to a larger, cash-generating CNS and addiction platform. SUPN's growth products now comprise 80% of revenue, with Qelbree and ZURZUVAE driving robust prescription and sales growth. Combined entity targets $2.2B revenue, $888M adjusted EBITDA, $125M synergies, and trades at ~7x synergized EBITDA—suggesting a mispriced, underappreciated value.